索他洛夫是一种具有非心脏选挥价β阻滞,以及Ⅲ类抗心律失常药性能的新药。此药是由其立体异构体d-和l-sotalol的消旋混合物构成的,其中d-stotalol仅有约1/50左旋复合物的β阻滞作用。在体内,索他洛尔似仅有约20％～50％普莱洛尔(心得安)的β阻滞效能。d,l-sotalol的β阻滞电生理作用包括延长房室结的窦性周期、A-H间期和有效不应期(ERP)。其Ⅲ类药作用为浓度依赖的 Sototalv is a new drug with non-cardiac blockbuster beta blockers and Class III antiarrhythmic drugs. The drug consists of a racemic mixture of its stereoisomers, d- and l-sotalol, with d-stotalol having only a beta block of about 1/50 of the L-complex. In vivo, sotalol seems to have only about 20% to 50% preelerol (propranolol) beta block potency. d, l-sotalol β-block electrophysiological effects include prolonging the sinus node, A-H interval and effective refractory period (ERP). Its class III effect is concentration-dependent